Generic availability depends on patent expirations and ongoing litigation. Liraglutide (Saxenda) patents expire in 2026-2027, potentially allowing generic entry soon after. Semaglutide formulations are protected by patents extending to 2031-2032, though some patent challenges are pending. Tirzepatide patents run through the mid-2030s. The complex manufacturing process for peptide-based GLP-1 medications creates additional barriers to generic competition beyond just patent expiration. Biosimilar versions (similar to generics for biologics) may enter the market first. Even when patents expire, the technical challenges of producing consistent, high-quality peptide medications at scale may delay affordable generic options for several years beyond patent expiration.
Find a qualified GLP-1 provider
Compare pricing, clinical oversight, and patient reviews across verified telehealth programs and local clinics.
Compare Providers →Still have questions?
A qualified GLP-1 provider can give you personalized answers based on your medical history and goals.
Get answers to your GLP-1 questions
Weekly updates with the latest research, pricing changes, and expert guidance — delivered to your inbox.
No spam. Unsubscribe anytime.
Ready to start your GLP-1 journey?
Compare verified providers on pricing, medication sourcing, clinical oversight, and patient reviews — all in one place.